Skip to main content

Table 4 Adverse Events Associated With Rivastigmine*

From: Current pharmacologic options for patients with Alzheimer's disease

Adverse Event†

Placebo (n = 868) (%)

Rivastigmine 6–12 mg/day (n = 1189) (%)

Nausea

12

47

Vomiting

6

31

Anorexia

3

17

Dyspepsia

4

9

Asthenia

2

6

  1. * Novartis Pharmaceuticals Corp.: Exelon® (rivastigmine tartrate) capsules [prescribing information]. East Hanover, NJ 2001. † Occurring in at least 5% of patients and at twice the placebo rate.
Back to article page

Annals of General Psychiatry

ISSN: 1744-859X